Cargando…
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
BACKGROUND: Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. METHODS: To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic agents....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475224/ https://www.ncbi.nlm.nih.gov/pubmed/36082809 http://dx.doi.org/10.1111/1759-7714.14603 |
_version_ | 1784789866284843008 |
---|---|
author | Feng, Yu Huang, Liling Zhu, Haohua Tang, Le Hu, Xingsheng Shi, Yuankai |
author_facet | Feng, Yu Huang, Liling Zhu, Haohua Tang, Le Hu, Xingsheng Shi, Yuankai |
author_sort | Feng, Yu |
collection | PubMed |
description | BACKGROUND: Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. METHODS: To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic agents. RESULTS: A total of 54 patients with NSCLC were enrolled into the study. Twelve (22.2%) who received a combination of antiangiogenic agents, when there was a trend of osimertinib resistance but did not reach imageology progressive disease (PD), were assigned to Group A, with a median overall survival (OS) and progression‐free survival (PFS) of 48.0 (95% CI, not reached) and 21.0 (95% CI: 16.7–25.3) months, respectively. Thirty (55.6%) who received a combination of antiangiogenic agents when there was imageology PD during treatment with osimertinib were assigned to Group B, with a median OS and PFS of 31.8 (95% CI: 26.6–37.1) and 9.2 (95% CI: 5.9–12.6) months, respectively. Twelve (22.2%) who received a combination of antiangiogenic agents at the initial treatment with osimertinib were assigned to Group C, with a median OS and PFS of 28.5 (95% CI: 15.2–41.8) and 15.3 (95% CI: 7.9–22.7) months, respectively. Patients in Group A achieved a significant prolonged median PFS (p < 0.001) compared with Groups B and C. Absence of epidermal growth factor receptor (EGFR) T790M mutations (p = 0.043; hazard ratio [HR] = 2.124, 95% CI: 1.023–4.413) and no previous antiangiogenic agent application (p = 0.012; HR = 0.362, 95% CI: 0.163–0.863) were the independent prognostic factors of OS. CONCLUSION: The well‐timed action to combine antiangiogenic agents was when there was a trend of osimertinib resistance. The absence of EGFR T790M mutations and previous use of antiangiogenic agents were poor prognostic factors. |
format | Online Article Text |
id | pubmed-9475224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-94752242022-09-28 The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study Feng, Yu Huang, Liling Zhu, Haohua Tang, Le Hu, Xingsheng Shi, Yuankai Thorac Cancer Original Articles BACKGROUND: Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. METHODS: To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic agents. RESULTS: A total of 54 patients with NSCLC were enrolled into the study. Twelve (22.2%) who received a combination of antiangiogenic agents, when there was a trend of osimertinib resistance but did not reach imageology progressive disease (PD), were assigned to Group A, with a median overall survival (OS) and progression‐free survival (PFS) of 48.0 (95% CI, not reached) and 21.0 (95% CI: 16.7–25.3) months, respectively. Thirty (55.6%) who received a combination of antiangiogenic agents when there was imageology PD during treatment with osimertinib were assigned to Group B, with a median OS and PFS of 31.8 (95% CI: 26.6–37.1) and 9.2 (95% CI: 5.9–12.6) months, respectively. Twelve (22.2%) who received a combination of antiangiogenic agents at the initial treatment with osimertinib were assigned to Group C, with a median OS and PFS of 28.5 (95% CI: 15.2–41.8) and 15.3 (95% CI: 7.9–22.7) months, respectively. Patients in Group A achieved a significant prolonged median PFS (p < 0.001) compared with Groups B and C. Absence of epidermal growth factor receptor (EGFR) T790M mutations (p = 0.043; hazard ratio [HR] = 2.124, 95% CI: 1.023–4.413) and no previous antiangiogenic agent application (p = 0.012; HR = 0.362, 95% CI: 0.163–0.863) were the independent prognostic factors of OS. CONCLUSION: The well‐timed action to combine antiangiogenic agents was when there was a trend of osimertinib resistance. The absence of EGFR T790M mutations and previous use of antiangiogenic agents were poor prognostic factors. John Wiley & Sons Australia, Ltd 2022-08-09 2022-09 /pmc/articles/PMC9475224/ /pubmed/36082809 http://dx.doi.org/10.1111/1759-7714.14603 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Feng, Yu Huang, Liling Zhu, Haohua Tang, Le Hu, Xingsheng Shi, Yuankai The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
title | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
title_full | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
title_fullStr | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
title_full_unstemmed | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
title_short | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
title_sort | exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: a real‐world study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475224/ https://www.ncbi.nlm.nih.gov/pubmed/36082809 http://dx.doi.org/10.1111/1759-7714.14603 |
work_keys_str_mv | AT fengyu theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT huangliling theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT zhuhaohua theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT tangle theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT huxingsheng theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT shiyuankai theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT fengyu explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT huangliling explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT zhuhaohua explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT tangle explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT huxingsheng explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT shiyuankai explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy |